Duopharma Biotech Berhad Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Leonard bin Abdul Shatar
Chief executive officer
RM 2.5k
Total compensation
| CEO salary percentage | 47.8% |
| CEO tenure | 16.8yrs |
| CEO ownership | n/a |
| Management average tenure | 1.8yrs |
| Board average tenure | 6.7yrs |
Recent management updates
Recent updates
Duopharma Biotech Berhad (KLSE:DPHARMA) Is Due To Pay A Dividend Of MYR0.005
Aug 27
Duopharma Biotech Berhad (KLSE:DPHARMA) Is Paying Out A Dividend Of MYR0.018
Apr 04Duopharma Biotech Berhad's (KLSE:DPHARMA) Intrinsic Value Is Potentially 24% Below Its Share Price
Feb 17These 4 Measures Indicate That Duopharma Biotech Berhad (KLSE:DPHARMA) Is Using Debt Extensively
Oct 21Duopharma Biotech Berhad (KLSE:DPHARMA) Has Announced A Dividend Of MYR0.005
Aug 18Calculating The Intrinsic Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)
Aug 07Duopharma Biotech Berhad's (KLSE:DPHARMA) Shareholders Will Receive A Smaller Dividend Than Last Year
Mar 28Calculating The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)
Mar 27We Think That There Are Issues Underlying Duopharma Biotech Berhad's (KLSE:DPHARMA) Earnings
Nov 26Need To Know: The Consensus Just Cut Its Duopharma Biotech Berhad (KLSE:DPHARMA) Estimates For 2021
Nov 25Duopharma Biotech Berhad's (KLSE:DPHARMA) Dividend Will Be RM0.005
Aug 20Here's Why Duopharma Biotech Berhad (KLSE:DPHARMA) Can Manage Its Debt Responsibly
May 22Duopharma Biotech Berhad (KLSE:DPHARMA) Investors Should Think About This Before Buying It For Its Dividend
Apr 13A Look At The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)
Mar 14Duopharma Biotech Berhad (KLSE:DPHARMA) Seems To Use Debt Quite Sensibly
Feb 12Do Institutions Own Duopharma Biotech Berhad (KLSE:DPHARMA) Shares?
Jan 28
Is Duopharma Biotech Berhad (KLSE:DPHARMA) The Right Choice For A Smart Dividend Investor?
Jan 12CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | RM 56m |
| Jun 30 2024 | n/a | n/a | RM 49m |
| Mar 31 2024 | n/a | n/a | RM 45m |
| Dec 31 2023 | RM 3k | RM 1k | RM 53m |
| Sep 30 2023 | n/a | n/a | RM 61m |
| Jun 30 2023 | n/a | n/a | RM 69m |
| Mar 31 2023 | n/a | n/a | RM 72m |
| Dec 31 2022 | RM 2m | RM 1m | RM 70m |
| Sep 30 2022 | n/a | n/a | RM 69m |
| Jun 30 2022 | n/a | n/a | RM 69m |
| Mar 31 2022 | n/a | n/a | RM 68m |
| Dec 31 2021 | RM 2m | RM 1m | RM 66m |
| Sep 30 2021 | n/a | n/a | RM 66m |
| Jun 30 2021 | n/a | n/a | RM 63m |
| Mar 31 2021 | n/a | n/a | RM 63m |
| Dec 31 2020 | RM 2m | RM 924k | RM 59m |
| Sep 30 2020 | n/a | n/a | RM 54m |
| Jun 30 2020 | n/a | n/a | RM 55m |
| Mar 31 2020 | n/a | n/a | RM 54m |
| Dec 31 2019 | RM 2m | RM 882k | RM 55m |
| Sep 30 2019 | n/a | n/a | RM 58m |
| Jun 30 2019 | n/a | n/a | RM 55m |
| Mar 31 2019 | n/a | n/a | RM 51m |
| Dec 31 2018 | RM 1m | RM 876k | RM 48m |
Compensation vs Market: Leonard's total compensation ($USD567.40) is below average for companies of similar size in the MY market ($USD153.60K).
Compensation vs Earnings: Leonard's compensation has been consistent with company performance over the past year.
CEO
Leonard bin Abdul Shatar (59 yo)
16.8yrs
Tenure
RM 2,533
Compensation
Encik Ariff bin Abdul Shatar, also known as Leonard, has been Group Managing Director of Duopharma Biotech Berhad (alternate name Duopharma Biotech Bhd) since December 28, 2017. Encik bin Abdul Shatar serv...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Group MD & Executive Director | 16.8yrs | RM 2.53k | no data | |
| Chief Financial Officer | 12.3yrs | no data | 0.000010% MYR 121.2 | |
| Chief Executive Officer of Group Operations | less than a year | no data | no data | |
| Chief Legal Officer & Group Company Secretary | 6.9yrs | no data | no data | |
| Chief Compliance Officer | 1.3yrs | no data | no data | |
| Chief Manufacturing & Sustainability Officer | 2.1yrs | no data | 0.00030% MYR 3.6k | |
| Chief Consumer Healthcare Officer | less than a year | no data | no data | |
| Group Head of Risk Management & Integrity | 1.8yrs | no data | no data | |
| Chief Innovation Officer | less than a year | no data | no data |
1.8yrs
Average Tenure
54yo
Average Age
Experienced Management: DPHARMA's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Group MD & Executive Director | 6.9yrs | RM 2.53k | no data | |
| Independent Non-Executive Director | less than a year | no data | no data | |
| Independent Non-Executive Director | 8.4yrs | RM 130.80k | no data | |
| Non Independent Non Executive Director | 6.7yrs | RM 146.40k | 0.0026% MYR 31.9k | |
| Independent Non-Executive Director | 6.9yrs | RM 143.80k | no data | |
| Independent Non-Executive Director | 5.2yrs | RM 135.40k | no data | |
| Independent Non Executive Director | 8.2yrs | RM 143.80k | no data | |
| Senior Independent Non-Executive Director | 8yrs | RM 141.40k | no data | |
| Non-Independent & Non-Executive Chairman | 1.4yrs | RM 76.70k | no data | |
| Non Independent & Non Executive Alternate Director | 1.3yrs | no data | no data | |
| Non-Independent & Non-Executive Director | less than a year | no data | no data |
6.7yrs
Average Tenure
64yo
Average Age
Experienced Board: DPHARMA's board of directors are considered experienced (6.7 years average tenure).